Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome

DNA Repair

Volumn 2, Issue 5, 2003, Pages 547-559

  Casorelli, Ida ^a,c   Offman, Judith ^b   Mele, Luca ^c   Pagano, Livio ^c   Sica, Simona ^c   D'Errico, Mariarosaria ^a   Giannini, Giuseppe ^d   Leone, Giuseppe ^c   Bignami, Margherita ^a   Karran, Peter ^b  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c CATHOLIC UNIVERSITY   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acute myeloid leukemia; Chemotherapy; Mismatch repair

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MITOMYCIN C; MITOXANTRONE; PACLITAXEL; PREDNISONE; PROCARBAZINE; PROTEIN MLH1; TAMOXIFEN; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA REPAIR; FEMALE; GENE MUTATION; GENE SILENCING; HODGKIN DISEASE; HUMAN; HUMAN CELL; KARYOTYPE; MALE; METHYLATION; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; SKIN CANCER; STEM CELL TRANSPLANTATION; THYROID CANCER; UTERUS CANCER;

EID: 0242418183     PISSN: 15687864     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1568-7864(03)00020-X     Document Type: Article

References (51)

1. Leone G., Voso M.T., Sica S., Morosetti R., Pagano L. Therapy related leukemias: susceptibility. Leuk. Lymphoma. 41:2001;255-276.
2. Pedersen-Bjergaard J., Andersen M.K., Christiansen D.H., Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood. 99:2002;909-912.
3. Pedersen-Bjergaard J., Philip P., Larsen S.O., Jensen G., Byrsting K. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood. 76:1990;1083-1091.
4. Leone G., Mele L., Pulsoni A., Equitani F., Pagano L. The incidence of secondary leukemias. Haematologica. 84:1999;937-945.
5. Pagano L., Pulsoni A., Tosti M.E., Avvisati G., Mele L., Mele M.et al. Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia. Br. J. Haematol. 112:2001;109-117.
6. Andersen M.K., Christiansen D.H., Jensen B.A., Ernst P., Hauge G., Pedersen-Bjergaard J. Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors. Br. J. Haematol. 114:2001;539-543.
7. Lynch H.T., Smyrk T.C., Watson P., Lanspa S.J., Lynch J.F., Lynch P.M.et al. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology. 104:1993;1535-1549.
8. Peltomaki P., Vasen H.F.A. HNPCC ICG. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. Gastroenterology. 113:1997;1146-1158.
9. Jiricny J., Nystrom-Lahti M. Mismatch repair defects in cancer. Curr. Opin. Genet Dev. 10:2000;157-161.
10. Kane M.F., Loda M., Gaida G., Lipman J., Mishra R., Goldman H.et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res. 57:1997;808-811.
11. Bearzatto A., Szadkowski M., Macpherson P., Jiricny J., Karran P. Epigenetic regulation of the MGMT and hMSH6 DNA repair genes in cells resistant to methylating agents. Cancer Res. 60:2000;3262-3270.
12. Karran P., Bignami M. DNA damage tolerance, mismatch repair and genome instability. BioEssays. 16:1994;833-839.
13. Branch P., Aquilina G., Bignami M., Karran P. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature. 362:1993;652-654.
14. Kat A., Thilly W.G., Fang W.-H., Longley M.J., Li G.-M., Modrich P. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc. Natl. Acad. Sci. U.S.A. 90:1993;6424-6428.
15. Swann P.F., Waters T.R., Moulton D.C., Xu Y.-Z., Zheng Q., Edwards M.et al. Role of post-replicative DNA mismatch repair in the cytotoxic action of thioguanine. Science. 273:1996;1109-1111.
16. Aebi S., Kurdi H.-B., Gordon R., Cenni B., Zheng H., Fink D.et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 56:1996;3087-3090.
17. Branch P., Masson M., Aquilina G., Bignami M., Karran P. Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells. Oncogene. 19:2000;3138-3145.
18. Fedier A., Schwarz V.A., Walt H., Carpini R.D., Haller U., Fink D. Resistance to topoisomerase poisons due to loss of DNA mismatch repair. Int. J. Cancer. 93:2001;571-576.
19. Tokunaga E., Oda S., Fukushima M., Maehara Y., Sugimachi K. Differential growth inhibition by 5-fluorouracil in human colorectal carcinoma cell lines. Eur. J. Cancer. 36:2000;1998-2006.
20. Carethers J.M., Chauhan D.P., Fink D., Nebel S., Bresalier R.S., Howell S.B.et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology. 117:1999;123-131.
21. Sill H., Goldman J.M., Cross N.C. Rarity of microsatellite alterations in acute myeloid leukaemia. Br. J. Cancer. 74:1996;255-257.
22. Ohyashiki J.H., Ohyashiki K., Aizawa S., Kawakubo K., Shimamoto T., Iwama H.et al. Replication errors in hematological neoplasias: genomic instability in progression of disease is different among different types of leukemia. Clin. Cancer Res. 2:1996;1583-1589.
23. Zhu Y.M., Das-Gupta E.P., Russell N.H. Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia. Blood. 94:1999;733-740.
24. Das-Gupta E.P., Seedhouse C.H., Russell N.H. Microsatellite instability occurs in defined subsets of patients with acute myeloblastic leukaemia. Br. J. Haematol. 114:2001;307-312.
25. Ben-Yehuda D., Krichevsky S., Caspi O., Rund D., Polliack A., Abeliovich D.et al. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood. 88:1996;4296-4303.
26. Sheikhha M.H., Tobal K., Yin J.A.L. High level of microsatellite instability but not hypermethylation of mismatch repair genes in therapy-related and secondary acute myeloid leukaemia and myelodysplastic syndrome. Br. J. Haematol. 117:2002;359-365.
27. Higuchi R., von Beroldingen C.H., Sensabaugh G.F., Erlich H.A. DNA typing from single hairs. Nature. 332:1988;543-546.
28. Dietmaier W., Wallinger S., Bocker T., Kullmann F., Fishel R., Ruschoff J. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res. 57:1997;4749-4756.
29. Rampino N., Yamamoto H., Ionov Y., Li Sawai H., Reed J.C., Perucho M. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science. 275:1997;967-969.
30. Parsons R., Myeroff L.L., Liu B., Willson K.V., Markowitz S.D., Kinzler K.W.et al. Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer. Cancer Res. 55:1995;5548-5550.
31. Kim N.G., Choi Y.R., Baek M.J., Kim Y.H., Kang H., Kim N.K.et al. Frameshift mutations at coding mononucleotide repeats of the hRAD50 gene in gastrointestinal carcinomas with microsatellite instability. Cancer Res. 61:2001;36-38.
32. Calin G., Ranzani G.N., Amadori D., Herlea V., Matei I., Barbanti-Brodano G.et al. Somatic frameshift mutations in the Bloom syndrome BLM gene are frequent in sporadic gastric carcinomas with microsatellite mutator phenotype. BMC Genet. 2:2001;14.
33. Giannini G., Ristori E., Cerignoli F., Rinaldi C., Zani M., Viel A.et al. Human MRE11 is inactivated in mismatch repair-deficient cancers. EMBO Rep. 3:2002;248-254.
34. Takeuchi S., Bartram C., Ludwig R., Royer-Pokora B., Schneider S., Imamura J.et al. Mutations of p53 in Wilms' tumors. Mod. Pathol. 8:1995;483-487.
35. Boland C.R., Thibodeau S.N., Hamilton S.R., Sidransky D., Eshelman J.R., Burt R.W.et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58:1998;5248-5257.
36. Loukola A., Eklin K., Laiho P., Salovaara R., Kristo P., Jarvinen H.et al. Microsatellite marker analysis in screening for hereditary nonpolyposis colorectal cancer (HNPCC). Cancer Res. 61:2001;4545-4549.
37. Herman J.G., Umar A., Polyak K., Graff J., Ahuja N., Issa J.et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. U.S.A. 95:1998;6870-6875.
38. R. Zanetti, P. Crosignani, S. Rosso, Cancer in Italy: Incidence Data From Cancer Registries, 1988-1992 (Lega Italiana per la lotta contro i tumori: Il pensiero scientifico editore), vol. 2, 1992.
39. Simpkins S.B., Bocker T., Swisher E.M., Mutch D.G., Gersell D.J., Kovatich A.J.et al. MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum. Mol. Genet. 8:1999;661-666.
40. Fleisher A.S., Esteller M., Wang S., Tamura G., Suzuki H., Yin J.et al. Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res. 59:1999;1090-1095.
41. Di Crook L., Raker V.A., Corsaro M., Fazi F., Fanelli M., Faretta M.et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science. 295:2002;1079-1082.
42. Venkitaraman A.R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 108:2002;171-182.
43. Garcia-Higuera I., Taniguchi T., Ganesan S., Meyn M.S., Timmers C., Hejna J.et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell. 7:2001;249-262.
44. Howlett N.G., Taniguchi T., Olson S., Cox B., Waisfisz Q., De Die-Smulders C.et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 297:2002;606-609.
45. Carney J.P., Maser R.S., Olivares H., Davis E.M., Le Beau M., Yates J.R. IIIet al. The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell. 93:1998;477-486.
46. Shiloh Y. Ataxia-Telangiectasia and the Nijmegen breakage syndrome: related disorders but genes apart. Annu. Rev. Genet. 31:1997;635-662.
47. Varon R., Reis A., Henze G., von Einsiedel H.G., Sperling K., Seeger K. Mutations in the Nijmegen Breakage Syndrome gene (NBS1) in childhood acute lymphoblastic leukemia (ALL). Cancer Res. 61:2001;3570-3572.
48. Fukuda T., Sumiyoshi T., Takahashi M., Kataoka T., Asahara T., Inui H.et al. Alterations of the double-strand break repair gene MRE11 in cancer. Cancer Res. 61:2001;23-26.
49. Bender C.F., Sikes M.L., Sullivan R., Huye L.E., Le Beau M.M., Roth D.B.et al. Cancer predisposition and hematopoietic failure in Rad50(S/S) mice. Genes Dev. 16:2002;2237-2251.
50. Moritz T., Mackay W., Glassner B.J., Williams D.A., Samson L. Retrovirus-mediated expression of a DNA repair protein in bone marrow protects hematopoietic cells from nitrosourea-induced toxicity in vitro and in vivo. Cancer Res. 55:1995;2608-2614.
51. 6-alkylguanine-DNA-alkyltransferase. Blood. 87:1996;1957-1961.